Grants & founds

Participation in selected research grants and projects:

1.     2026–2030. Multiomics dissection of hierarchical translatome reprogramming via regulome- and epitranscriptome-mediated translational control. Master A (US). Grant proposal submitted to the Polish Returns NAWA 2025 programme, Application no. BPN/PPO/2025/1/00066, Narodowa Agencja Wymiany Akademickiej (NAWA), Warsaw, PL. Total projected budget: EUR 566,504. The project is supported by the host institution, the Institute of Mother and Child (IMiD) in Warsaw, Department of Medical Genetics. Role: Principal investigator, author of the scientific concept, formulation of research hypotheses, definition of work packages, methodologies, and milestones, as well as overall project coordination within the planned Laboratory of Epitranscriptomics and Translational Control at IMiD. Abstract.

2.      2025-2029. Multiomics dissection of gut microbiome–epigenome reprogramming driven by functional food intervention (NUMIEP). Koronowicz A (PL), Master A (US), Doskočil I (CZ), Stefanska B (CA). International grant proposal submitted 15 Dec 2025, OPUS-30 (LAP) ID: 660523, NCN (PL) and GACR (CZ). Role: scientific concept, formulation of research hypotheses, and definition of work packages, methods, and milestones. My role: USA consortium partner (in-kind contribution); scientific concept co-author (microbiome-epigenome-transcriptome axis).

3.         2024–present. Development of an AI-Driven Multiomics Platform for the Discovery of Cancer Biomarkers and Therapeutic Targets. Author and Principal Investigator: Adam Master, Gednasa LLC, New York, USA. The project focuses on the development of an AI-driven multiomics platform integrating epigenomic, transcriptomic, epitranscriptomic, regulomic, and translatomic data to enable the discovery of cancer-related biomarkers and therapeutic targets. The research aims to advance precision medicine and next-generation therapeutics, with particular emphasis on oncology and translational applications. Responsibilities include project conception and design, scientific leadership, development of the multiomics platform, advanced data analysis, coordination of international collaborations, and oversight of biomarker and therapeutic target identification, including evaluation of their potential for clinical trial development. Funding: The project is supported by external private investments.

4.     2019–2021. Drug Resistance in Advanced Non-Small Cell Lung Cancer (NSCLC). National Institutes of Health (NIH, USA), Grant No. BU00002238, Total budget: $438,625, Federal. Adam Master was an investigator (postdoctoral associate), leading a group responsible for the genomic component, including pharmacogenomic, transcriptomic, and proteomic profiling (whole-genome and SNP analyses). Coordinated the team for data generation, integration, and interpretation to support downstream in vivo and in vitro mechanistic studies, leading to the identification of β-catenin pathway mutations as a mechanism of drug resistance. This project was a continuation of research initiated under NIH grants R01CA09242308, R01CA139454, and R01CA154172.

5.     2020–2023. Molecular Analysis of Ocular Surface Tissues in Response to Dry Eye Disease and Osmotic Stress. National Institutes of Health (NIH, USA), Federal / Stony Brook Medicine, Grant No. IRB2019-00659. Adam Master was an investigator, leading a group dealing with the genomic, transcriptomic, and proteomic component, including large-scale bioinformatic analyses. He provided integrative datasets to guide in vivo and in vitro mechanistic studies in rabbit dry eye disease (an autoimmune model), and contributed to the design and support of downstream experimental validation. Outcomes include three first-author publications (GEO: GSE171043, PMID: 34841993, 34742691, 34324523) and additional co-authored publications (PMID: 34964663).

6.     2021–2026. Prevention of Chemotherapy-Induced Neuropathy and Neuropathic Pain. State University of New York / Stony Brook University. Adam Master was an investigator, leading a group responsible for high-throughput transcriptomic and proteomic analyses in mouse dorsal root ganglia and sciatic nerve tissues. He supervised research staff and students, performed integrative bioinformatic analyses, and designed mechanistic gain- and loss-of-function experiments to validate key transcriptional and translational pathways. This work produced publicly available datasets (GEO: GSE249643) and a peer-reviewed publication (PMID: 38347876), with additional publications in preparation (2026).

7.       2012–2016. Research project: Conjugated Linoleic Acid (CLA)-Induced Transcriptional Activation of PPAR – Investigation of Molecular Mechanisms of Putative Anticancer Action of Fatty Acids from CLA-Enriched Egg Yolks. Supported by the National Science Centre (NCN), Grant No. UMO-2011/03/B/NZ9/01423. Adam Master was a co-author of the concept and an investigator responsible for genetic, transcriptomic and bioinformatic analyses. This work resulted in several peer-reviewed publications (PMID: 28458685, 26799209, 27551323).

8.       2009-2016;  Research project: Structural and Functional Analysis of Splice Variants of TRβ1 in Human Renal Cancer. Supported by the Polish State Committee for Scientific Research (Grants N N401 073636, N401 017 32/0286) and the Medical Centre of Postgraduate Education (Grant 501-2-1-22-15/06). Conducted at The Medical Centre of Postgraduate Medical Education (CMKP), Warsaw, Poland. Adam Master was the lead investigator and the first-author of several publications (PMID: 20691260, 27171412, 25033541; THRB, Atlas Genet Cytogenet Oncol Haematol. 2014;18(6); Post. Biol. Kom. 2014;41(1):3–28 and 41(1):29-58), as well as co-authored publications (PMID: 24849932, 17910524, 21912701, 17726548).
Other NCN/CMKP grant projects realized during PhD research on the role of untranslated regions of thyroid hormone receptor beta (TRβ) mRNAs in clear cell renal cell carcinoma (ccRCC) as part of his PhD studies followed by his research (2005–2016), at The Center of Postgraduate Medical Education (CMKP). Wasaw, PL:

9.       Project No. N N401 3547 33, focusing on thyroid hormones and cancer,

10.      Project No. N401 017 32/02863, focusing on thyroid hormones and cancer biology,

11.      Project No. 501-2-1-24-06/08, focusing on thyroid hormone receptor biology and cancer,

12.      Project No. 501-2-1-24-07/08, focusing on thyroid hormone receptor signaling  in cancer,

13.      Project No. 501-2-1-22-15/06, focusing on thyroid hormone receptor translational regulation in renal cancer.

14.     2005-2011, Adam Master - Author and Principal Investigator and leader of an 11-member research team of the project: Gene synthesis using the method of oligonucleotide assembly in PCR reaction, co-financed by the European Union from the European Regional Development Fund (ERDF) as part of the Integrated Regional Operational Programme (IROP), Project no.: Dz.3.4/ML/2/05, ZPORR (16.09.2005). The project with a total value of 776915 PLN gross (about $200,000 07/12/2024) was realized in Laboratory of Nucleic Acid Synthesis and Sequencing of BioTe21 link. The structural fund of EU allowed to provide the best quality, the most advanced research tools and high-resolution apparatus enable of performing the synthesis and analysis at genome and transcriptome level (ABI 3900 High-Throughput DNA Synthesizer, ABI 3100 Automated Capillary DNA Sequencer, HPLC, lyophilizer, thermocyclers and other tools. Project partner: AME Bioscience Ltd, UK. Among other achievements, the project enabled the development of an improved optimization of improved gene sequences allowing for the most efficient protein synthesis (gene engineering) as well as the discovery of a new approach to enhancing translation of selected protein isoforms. The method was successfully used to enhance the translation of THRB and CDKN2A tumor suppressors (Master et al. 2016). It has also been cited and used as a reference in Roche's patent WO2023111337A1 (2023) and cited by Ionis Pharmaceuticals’ patent EP3313989B1 (2024) on Google Patents. This demonstrates that the method discovered by Adam Master is gaining international recognition, as reported in a patent attorney's opinion on the novelty of the concept of invention PL237080B1 link. 

15.    2007–2009, Adam Master, author and PI of the project: Genetic predisposition diagnostics for cancer, carried out at the Laboratory of Molecular Genetics, Nucleagena (currently Synevo), Janowo Zembrzus, Warmian–Masurian Voivodeship, PL. The project was financed by the European Commission under the European Regional Development Fund (ERDF) within the Integrated Regional Operational Programme (ZPORR) 2004–2006, Action 3.4, Project code Z/12/III/3.4/391/05. The total indicative investment cost amounted to EUR 3,120,000. The project focused on the development and implementation of advanced molecular genetic diagnostics for cancer predisposition, strengthening regional research infrastructure and enabling the application of innovative molecular biology methods in clinical and translational research.

16.    2009–2011. Large project: Expression of Genes Involved in Human Epilepsy (research using RNA microarras), coordinated by Adam Master as Principal Investigator at the Laboratory of Molecular Medical Biology, BioTe21, in cooperation with the Medical University of Lublin, Poland, and Ocean Ridge Biosciences, Palm Beach Gardens, FL, USA. Funding: Medical University of Lublin.

17.    2008–2010. Adam Master – Author and Principal Investigator. Project: Genetic Diagnostics of Inherited Mutations of Genes Involved in Melanoma Malignum, realized in the Laboratory of Molecular Medical Biology, BioTe21. Funding: private external investments supported by PKO BP. The project outcome received the Malopolska Innovator Award 2009 for melanoma diagnostics and innovative biotechnologies.

18.     2007–2012. Participation in an international project proposal: Beta-Carotene Metabolism as a Risk Factor for Liver Fat Accumulation – Search for Novel NAFLD Risk Markers, prepared for the 7th EU Framework Programme (FP7), Health priority, coordinated by Collegium Medicum, Jagiellonian University. Adam Master served as Principal Investigator and Director of the Medical Genetics Laboratory at BioTe21 (entrepreneurial consortium partner).

19.    2005–2011. Participation in several biomedical projects coordinated by AKCENT MALOPOLSKA, a consortium of Jagiellonian University, Cracow University of Technology, University of Agriculture, and AGH University of Science and Technology. The projects were part of a research programme covering priority areas including biotechnology, nanotechnology, and modern technologies in medicine. The consortium aimed to conduct long-term interdisciplinary research and training, as well as to promote the implementation and commercialization of modern technologies by the participating universities in Krakow. Adam Master served as Principal Investigator and Director of the Medical Genetics Laboratory at BioTe21 within the consortium.